Thalidomide analog appears worthy opponent of sickle cell disease

July 18, 2011 in Medical research

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

Much like hydroxyurea, the only Food and Drug Administration-approved therapy for , pomalidomide increases production of fetal hemoglobin which, unlike its adult counterpart, cannot take on the destructive sickle shape.

In stark contrast, pomalidomide also preserves function actually increasing proliferation of the cells that make oxygen-carrying , GHSU researchers report in the journal Blood. Hydroxyurea is known to suppress bone marrow function, potentially leaving patients susceptible to infection and bleeding.

"We were thrilled to find that pomalidomide stimulated fetal hemoglobin expression without toxicity to the bone marrow and increased productions of red in the face of anemia," said Dr. Steffen E. Meiler, , Vice Chairman of Research in the GHSU Department of Anesthesiology and Perioperative Medicine and the study's corresponding author.

The study compared pomalidomide to hydroxyurea as well as a combination of the drugs in a of sickle cell disease. After eight weeks, both pomalidomide and hydroxyurea increased fetal hemoglobin but only pomalidomide was kind to the bone marrow. Surprisingly, when the drugs were given together, all benefits were lost.

"We are excited and optimistic about pomalidomide doing the same thing for patients meaning it will boost their fetal hemoglobin and boost their red blood cells," said Dr. Abdullah Kutlar, Director of the GHSU Sickle Cell Center and a study co-author. "If we can do that, it will be the best of both worlds," added Kutlar also is a principal investigator on a phase 1 trial pursuing the drug's patient potential.

Despite its notorious reputation for causing birth defects, thalidomide and now its analogs are carving out a potentially positive future for their ability to regulate the immune response. In fact, it was the inflammation-fighting ability of the analog lenalidomide that GHSU researchers wanted to study. Inflammation, another sickle cell disease hallmark, results when white blood cells attack the abnormal- looking red blood cells as well as the sickle-shaped cells injuring the blood vessel wall lining.

Lenalidomide already is approved for anemia as well as a cancer of the white blood cells called multiple myeloma and is currently under study for other cancers. When GHSU researchers approached drug-maker Celgene Corporation about the study, the New Jersey-based company shared laboratory evidence that pomalidomide, a more potent and closely related cousin of lenalidomide, had the added benefit of increasing fetal hemoglobin expression and proliferation of CD34+ progenitor cells, which make red blood cells. When the researchers looked at pomalidomide's impact on fetal hemoglobin and bone marrow function in their mouse model, they found similar results.

"Pomalidomide produced about as much as hydroxyurea but the bone marrow was entirely intact," Meiler said. The laboratory work prompted them to initiate a Phase 1 clinical trial of the drug for sickle cell disease with Wayne State University in Michigan. Because of past experience with , women of child-bearing age receive a pregnancy test and contraception counseling before entering the study. Participants taking pomalidomide also can't have taken for at least several months to help ensure any results are from the newer drug.

Sickle cell is a genetic disease affecting 1 in 500 blacks in the United States.

Provided by Georgia Health Sciences University

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • portable metabolism meter?
    createdMay 21, 2012
  • Rare medical conditions on 20/20 tonight
    createdMay 18, 2012
  • "Good" Cholesterol in Doubt
    createdMay 17, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Implantable pain disk may help those with cancer

An estimated 3.5 million cancer patients around the globe are in severe pain from their disease, but many get no relief.

Medical research created 6 hours ago | popularity not rated yet | comments 0 | with audio podcast

Energy levels link sleep control mechanisms

Sleep, or lack of it, can determine level of cognitive performance which is linked with accidents as well as increased risk of serious health problems. Links between cell energy levels, gene transcription ...

Medical research created 8 hours ago | popularity not rated yet | comments 0

Researchers identify key brain cell in antidepressant action

(Medical Xpress) -- Antidepressant medications such as Prozac have helped improve mood and lessen anxiety in millions of people with major depression. But scientists know surprisingly little about how these drugs work.

Medical research created 8 hours ago | popularity not rated yet | comments 0 | with audio podcast

Rockefeller scientists pioneer new method to determine mechanisms of drug action

(Medical Xpress) -- Knowing that a drug works is great. Knowing how it works is a luxury. And until now, determining a drug’s mechanism of action has been a tedious and difficult process for scientists.

Medical research created 8 hours ago | popularity not rated yet | comments 0 | with audio podcast

Like curry? New biological role identified for compound used in ancient medicine

Scientists have just identified a new reason why some curry dishes, made with spices humans have used for thousands of years, might be good for you.

Medical research created 16 hours ago | popularity 4.3 / 5 (4) | comments 1 | with audio podcast


Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

First study to suggest that the immune system may protect against Alzheimer's changes in humans

Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.